Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Total Liabilities
Everything the company owes to creditors and other parties.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 131.9% from a year ago
Total liabilities stood at $157.69M at the end of Q1 FY2026, up 131.9% from a year earlier and up 119.6% from the prior quarter. Over 3 fiscal years it compounded at +106.7% a year.
Context
- Total liabilities amounted to 81.4% of total assets at the end of Q1 FY2026, down 28.5 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +131.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 71.79M USD
- Year-over-year change
- +15.1%
- 4-year CAGR
- +77.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.79M | +15.1% |
| FY2024 | 2024-12-31 | 62.35M | +6.7% |
| FY2023 | 2023-12-31 | 58.46M | +618.6% |
| FY2022 | 2022-12-31 | 8.14M | +12.2% |
| FY2021 | 2021-12-31 | 7.25M | — |
Total Liabilities vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +131.9% is the highest of 8, against a peer median of +3.8%.
- Total liabilities amounts to 81.4% of total assets for MIST, versus a peer median of 29.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $157.69M USD | +131.9% | +106.7% | 81.4% | |
| Dec 2025 | €84.39M EUR | -17.4% | -18.1% | 134.6% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $24.13M USD | +25.4% | +20.8% | 106.3% |
| Mar 2026 | $22.32M USD | -37.3% | -11.2% | 14.3% | |
| Mar 2026 | CHF 19.15M CHF | +48.4% | -7.0% | 21.9% | |
| Mar 2026 | $18.14M USD | +41.4% | -14.7% | 12.6% | |
| Mar 2026 | $16.34M USD | -44.6% | -20.5% | 31.5% | |
| Mar 2026 | $14.46M USD | +3.8% | +18.8% | 29.4% | |
| Peer median (excluding MIST) | — | +3.8% | -11.2% | 29.4% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114.14M | 7.64M | 13.76M | 25.31M | 73.05M |
| Short-term Investments | 0 | 56.95M | 52.24M | 44.38M | 32.91M |
| Net Receivables | 483K | 1.21M | 3.85M | 2.39M | 3.51M |
| Inventory | 0 | 0 | 0 | 0 | 648K |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 118.92M | 71.8M | 73.03M | 73.93M | 111.92M |
| Property, Plant & Equipment (Net) | 926K | 2.68M | 2.19M | 1.57M | 1.64M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 926K | 2.68M | 2.19M | 1.57M | 1.64M |
| Total Assets | 119.85M | 74.48M | 75.23M | 75.5M | 113.56M |
| Account Payables | 4.38M | 2.26M | 3.98M | 1.93M | 5.65M |
| Short-term Debt | 224K | 495K | 0 | 0 | 647K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 709K | 808K | 1.99M | (0) | 5.23M |
| Total Current Liabilities | 6.78M | 6.14M | 7.23M | 8.13M | 13.98M |
| Long-term Debt | 0 | 0 | 49.77M | 53.35M | 57.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 83K |
| Total Non-current Liabilities | 474K | 2M | 51.23M | 54.23M | 57.81M |
| Total Liabilities | 7.25M | 8.14M | 58.46M | 62.35M | 71.79M |
| Common Stock | 251.9M | 273.9M | 260.5M | 288.05M | 352.62M |
| Retained Earnings | (206.32M) | (266.34M) | (326.03M) | (367.55M) | (430.6M) |
| Accumulated OCI | 51.31M | 34.35M | 48.46M | 53.08M | 55.65M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 112.6M | 66.35M | 16.77M | 13.15M | 41.77M |
| Total Debt | 698K | 2.49M | 51.78M | 54.8M | 58.38M |
| Net Debt | (113.44M) | (5.15M) | 38.02M | 29.48M | (14.67M) |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.